Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback